This talk is a historical perspective of insulin therapy over 30 years
At the start is was counted as a negtive for type 2 then became an absolute necessity to finally setting into 2022 as somewhere in between
The current focus is treating diabetes with patient at the core; with goals of treating and preventing cardiorenal complications/ getting a1c to goal; patient preferences with minimal hypoglycemia;
We has so many options in 2022 and finally treating diabetes is really a team event.
At the conclusion of this session, participants will be able to:
There are no questions yet...